Replies to post #6638 on Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

ABUS 1Q23 results—3/31/23 cash=$178.5M:

https://www.globenewswire.com/news-release/2023/05/04/2661394/14025/en/Arbutus-Reports-First-Quarter-2023-Financial-Results-and-Corporate-Update.html

ABUS still expects to start a phase-1 trial for AB-343, a SARS-CoV-2 protease inhibitor, in 2H23.